Apellis Pharmaceuticals Inc (APLS)
26.27
-1.79
(-6.38%)
USD |
NASDAQ |
Nov 15, 16:00
26.35
+0.08
(+0.30%)
After-Hours: 20:00
Apellis Pharmaceuticals Research and Development Expense (TTM): 320.50M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 320.50M |
| June 30, 2024 | 311.35M |
| March 31, 2024 | 329.06M |
| December 31, 2023 | 354.39M |
| September 30, 2023 | 384.53M |
| June 30, 2023 | 400.32M |
| March 31, 2023 | 406.32M |
| December 31, 2022 | 387.24M |
| September 30, 2022 | 390.99M |
| June 30, 2022 | 383.52M |
| March 31, 2022 | 427.80M |
| December 31, 2021 | 420.87M |
| September 30, 2021 | 368.02M |
| June 30, 2021 | 373.50M |
| March 31, 2021 | 314.65M |
| December 31, 2020 | 299.92M |
| September 30, 2020 | 328.06M |
| Date | Value |
|---|---|
| June 30, 2020 | 286.17M |
| March 31, 2020 | 249.77M |
| December 31, 2019 | 220.97M |
| September 30, 2019 | 173.30M |
| June 30, 2019 | 151.52M |
| March 31, 2019 | 128.36M |
| December 31, 2018 | 105.29M |
| September 30, 2018 | 87.61M |
| June 30, 2018 | 67.59M |
| March 31, 2018 | 50.48M |
| December 31, 2017 | 40.30M |
| September 30, 2017 | 32.76M |
| June 30, 2017 | 29.48M |
| March 31, 2017 | 22.99M |
| December 31, 2016 | 19.50M |
| September 30, 2016 | 15.80M |
| December 31, 2015 | 11.56M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
220.97M
Minimum
Dec 2019
427.80M
Maximum
Mar 2022
347.90M
Average
361.21M
Median
Research and Development Expense (TTM) Benchmarks
| Biomarin Pharmaceutical Inc | 779.92M |
| Ionis Pharmaceuticals Inc | 912.60M |
| EyePoint Pharmaceuticals Inc | 107.45M |
| Cassava Sciences Inc | 67.84M |
| Macrogenics Inc | 185.66M |